即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 955365-80-7 | 货号 | BCP01928 |
中文名 | Adavosertib | ||
英文名 | Adavosertib | ||
中文别名 | |||
英文别名 | MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775;MK-1775; | ||
SMILES | CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O | ||
化学名称 | |||
分子式 | C27H32N8O2 | 分子量 | 500.6 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Adavosertib is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. |
相关产品推荐
查看更多 >Tags:Adavosertib 供应商,Adavosertib 购买,Adavosertib 生产,Adavosertib 批量,Adavosertib 供应,Adavosertib 订购,Adavosertib 采购